# US 11,439,697 B2 · Nant cancer vaccine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,439,697 B2
- Document ID: US11439697B2
- Status: Granted
- Kind: B2
- Application number: 17/391,694
- Filed: 2021-08-02
- Published: 2021-11-18
- Granted: 2022-09-13
- Earliest claimed: 2016-06-30
- Assignees: NantCell, Inc.; Nant Holdings IP, LLC
- Applicants: NantCell, Inc.; Nant Holdings IP, LLC
- Inventors: Patrick Soon-Shiong; Kayvan Niazi; Shahrooz Rabizadeh; Hans G. Klingemann; Laurent H. Boissel; Barry J. Simon
- Web page: https://patentgrep.com/patent/US11439697B2

## CPC

- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 38/2013: {IL-2}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/282: Platinum compounds
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 31/565: not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 33/24: Heavy metals; Compounds thereof
- A61K 38/20: Interleukins [IL]
- A61K 38/2046: {IL-7}
- A61K 38/2086: {IL-13 to IL-16}
- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61K 40/4205: {Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4}
- A61K 40/4242: {Transcription factors, e.g. SOX or c-MYC}
- A61K 40/4253: {GTPases, e.g. Ras or Rho}
- A61K 40/4257: {Mucins, e.g. MUC-1}
- A61K 40/4266: {Carcinoembryonic antigen [CEA]}
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/22: against growth factors {; against growth regulators}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- A61K 2039/523: {expressing foreign proteins}
- A61K 2039/5256: {expressing foreign proteins}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- A61K 2239/54: Pancreas
- A61K 2239/55: Lung
- A61K 2239/57: Skin; melanoma
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Cancer is treated using coordinated treatment regimens that uses various compounds and compositions that drive a tumor from the escape phase of cancer immunoediting to the elimination and equilibrium phase of cancer immunoediting.

## Claims

### Claim 1

A method of treating cancer in a patient in need thereof, the method comprising:
administering to the patient a sequence of therapeutics,
wherein the sequence comprises a platinum chemotherapeutic, Nab-paclitaxel, haNK cells, an antibody for binding PD-L1, and IL-15 or IL-15N72D;
wherein the therapeutics are administered in cycles; and
wherein within the cycle the platinum chemotherapeutic and Nab-paclitaxel are administered before the haNK cells, PD-L1 antibody, and IL-15 or IL-15N72D.

### Claim 2 (depends on 1)

The method of claim 1, wherein the PD-L1 antibody is avelumab.

### Claim 3 (depends on 1)

The method of claim 1, wherein the IL-15N72D is ALT-803.

### Claim 4 (depends on 1)

The method of claim 1, wherein the platinum chemotherapeutic is administered on day 1 of the cycle.

### Claim 5 (depends on 4)

The method of claim 4, wherein the Nab-paclitaxel is administered on days 1 and 15 of the cycle.

### Claim 6 (depends on 5)

The method of claim 5, wherein the haNK cells are administered on day 9 of the cycle.

### Claim 7 (depends on 6)

The method of claim 6, wherein the platinum chemotherapeutic, the PD-L1 antibody, the haNK cells, and the Nab-paclitaxel are administered intravenously (IV), and wherein the ALT-803 is administered subcutaneously.

### Claim 8 (depends on 7)

The method of claim 7, wherein the platinum chemotherapeutic is cisplatin.

### Claim 9 (depends on 8)

The method of claim 8, wherein the cisplatin dose comprises 125 mg.

### Claim 10 (depends on 9)

The method of claim 9, wherein the haNK dose comprises 2×109 cells.

### Claim 11 (depends on 10)

The method of claim 10, wherein the antibody dose comprises 10 mg/kg.

### Claim 12 (depends on 11)

The method of claim 11, wherein the ALT-803 dose comprises 10 μg/kg.

### Claim 13 (depends on 12)

The method of claim 12, wherein the sequence further comprises 5-fluorouracil (5-FU).

### Claim 14 (depends on 13)

The method of claim 13, wherein the 5-FU dose comprises 400 mg/m2, administered by continuous IV infusion over at least 24 hours.

### Claim 15 (depends on 14)

The method of claim 14, wherein the sequence further comprises doxorubicin.

### Claim 16 (depends on 15)

The method of claim 15, wherein the doxorubicin dose comprises 20 mg/m2.

### Claim 17 (depends on 16)

The method of claim 16, wherein the sequence further comprises bevacizumab.

### Claim 18 (depends on 17)

The method of claim 17, wherein the bevacizumab dose comprises 5 mg/kg.

### Claim 19 (depends on 18)

The method of claim 18, wherein the doxorubicin and bevacizumab are administered IV.

### Claim 20 (depends on 1)

The method of claim 1, wherein the cycles are weekly, every two weeks, or every three weeks.